|
[1]Mckinlay,J. , & Marceau,L. US public health and the 21 sl century: Diabetes Mellitus. The Lancet 2000; 356 [9231]: 757-76 1. [2]Jonathan B. Brown, Kathryn L. Pedula, Alan W. Bakst. The Progressive Cost of Complications in Type 2 Diabetes Mellitus Arch Intern Med. 1999; 159: 1873-1880. [3]黃瀞儀︰門診糖尿病患對糖尿病知識、態度、行為與糖尿病需求之研究。健康促進暨衛生教育雜誌 1998;18:25-35。 [4] Gimeno-Orna, J.A., et al., Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol,2009.103(10):p.1364-1367. [5]Apelqvist, J., Diagnostics and treatment of the diabetic foot. Endocrine, 2012. [6] Tu, S.T., et al., Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus. Arch Intern Med, 2010.170(2):p.155-161. [7]Brown, M.J. and A.K, Asbury, Diabetic Neuropathy. Ann Neurol, 1984.15:p.2-12. [8]Chew, E.Y., Metabolic control and progression of retinopathy: The diabetes in early pregnancy study. National institute of child health and human development diabetes in early pregnancy study. Diabetes Care, 1995.18:p.631-637. [9] Reaven, G.M., Role of insulin resistance in human disease. Diabetes,988.37(1):p.595-607. [10] Keskin, M., et al., Homeostasis model assessment is more reliable than the fasting glucose/Insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics, 2005.115:p.500-503. [11] Howard, B.V., Insulin resistance and lipid metabolism. Am J Cardiol, 1999.84:p.28-32. [12] Brownlee, M., Biochemistry and molecular cell biology of diabetic complications.Nature, 2001.414(6865):p.813-820. [13] Chung, S.S., et al., Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol, 2003.14(8 Suppl 3):p.S233-236. [14] Toth, E., et al., Contribution of polyol pathway to arteriolar dysfunction in [15] 吳金洌. 再生醫學. 編輯地未知 : 幹細胞與組織工程 教學資源中心, 2008. [16] MarsonChris 且 DunnillPeter. A brief definition of regenerative medicine. future medicine. 2008年, 頁 1-5. [17]Semenkovich CF, Heinecke JW. (1997) The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 46:327-334. [18]吳宜真.奈米構形膠原蛋白結合Nicotinamide及Exendin-4誘導間質幹細胞成胰島素分泌細胞之研究.頁 16-18. [19]吳宜真.奈米構形膠原蛋白結合Nicotinamide及Exendin-4誘導間質幹細胞成胰島素分泌細胞之研究.2014. [20]武曉泓茅曉東, 徐寬楓, 崔岱, 朱劍劉翠萍,. Effect of nicotinamide and Extendin-4 on transdifferentiation of rat bone marrow mesenchymal stem cells (BM-MSC) into insulin producing cells. China J Diabetes. 2006年, 頁 14(3):230-232. [21] Nachnani JD, Nookala A, Herndon B, Molteni A, Pandya P, et alBulchandani. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010年, 頁 53(1):153-159. [22] Ahmad SRJ.Swann. Exenatide and rare adverse events. N Engl J Med. 2008年, 頁 358(18):1970-1971. [23] Wang QPLBrubaker. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002年, 頁 45(9):1263-1273. [24]郭士民、朱志勳.奈米構形膠原蛋白結合Nicotinamide及Exendin-4誘導間質幹細胞 成胰島素分泌細胞之研究.2013. [25]郭士民、吳宜真.奈米構形膠原蛋白結合Nicotinamide及Exendin-4誘導間質幹細胞成胰島素分泌細胞之研究.2014. [26]Bate KL, Jerums G.(2003) Preventing complications of diabetes. Med J Aust 179:498-503. [27]Chelliah A, Burge MR.(2004) Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 21:511-530. [28]中華民國糖尿病衛教學會,認識糖尿病(生理).2008. [29]郭怡婷,林時逸,許惠恒,糖尿病緩解之定義與新進展,2013年. 台中榮民總醫院內科部內分泌暨新陳代謝科 [30]Srikanta S, Ricker AT, McCulloch DK, Soeldner JS, Eisenbarth GS, Palmer JP.(1986) Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 35:139-142. [31]李靜宜. 肥胖糖尿病大白鼠模式之建立. 2004. [32]2013年美國糖尿病學會臨床治療指引摘要. 黃蘭菁, 等, 等. 4, 2013年, 台北市醫師公會會刊, 第 57 冊. [33]Standards of Medical Care in Diabetes—2010. AMERICAN DIABETES ASSOCIATION. [34]姜為棟. 第二型糖尿病動物新模型建立. 2007. [35] ItoMaeda, R., Ishida, S., Sasaki, H. and Harada, H.C.,. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Reaserch and Clinical Practice 50. 2000年, 頁 225-230. [36] BalkanForhan, A., Simon, D. and Eschwege , E.B.,. HbA1c as a diagnosti tool for diabetes. . International Congress Series 1253. 2003年, 頁 19-26. [37] BellG and K. S. Polonsky.I. Diabetes mellitus and genetically programmed defects in B-cell function. Nature. 2001年, 頁 414:788-791. [38]衛生福利部. 104 年死因統計結果分析. 2015年. [39]Reaven,G.M.,Role of insuiin resistance in human disease.Diabetes,1988.37(1):p.595-607. [40]Keskin,M., et al.,Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitativ insulin sensitvity check index for assessing insulinresistance among obese children and adolescents.pediatrics,2005.115:p.500-503. [41]Sigal, R.J., et al., Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care,2006. 29(6): p. 1433-1438. [42]Fryar, C.D., et al., Hypertension, high serum total cholesterol, and diabetes: racial and ethnic prevalence difference in U.S. adults, 1999-2006. NCHS Data Brief, 2010. 39: p.1.-8. [43]Howard, B. V., Insulin resistance and lipid metabolism. Am J Cardiol, 1999. 84: p.28-32. [44]Baptiste-Roberts K., et al., Risk factors for type 2 diabetes among women with gestational disbetes: a systematic review. Am J Med, 2009. 122(3): p.207-214. [45]Katon, J., et al., Hemoglobin a l c and postpartum abnormal glucose tolerance among women with gestational diabetes mellitus. Obstet Gynecol, 2012. 119(3): p. 566-574. [46]National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 1979. 28: p. 1039-1057. [47]Srikanta, S., et al., Autoimmunity ti insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes, 1986. 35(2): p.139-142. [48]Trachtenbarg, D.E., Diabetic ketoacidosis. Am Fam Physician, 2005. 71(9): p.1705-1714. [49]Rolo AP, Palmeira CM. (2006) Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212:167-178. [50]Semenkovich CF, Heinecke JW. (1997) The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 46:327-334. [51]Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP. (2006) Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diabetes Care 29:2252-2256. [52] A.J.M.,et al, Diabetic neuropathies: A statement by the American Diabetes Association Diabetes Care, 2005: p. e 28:4 956-962. [53] Bleyer, A.J., et al., Polyol pathway mediates high glucose-induced collagen synthesis in proximal tubule. Kidney Int, 1994. 45(3): p. 659-66. [54] Mitrakou, A., et al., Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes, 1990. 39: p.1381-1390. [55]Saltiel, A.R., The molecular and physiological basis of insulin resistance. J Clin Ivest, 2000. 106: p. 165-170. [56]Carrara, M.A., et al., Coexistence of insulin resistance and increased glucose tolerance in pregnant rats: A physiological mechanism for glucose maintenance. Life Sci, 2012. [57]Conner EM, Grisham MB.(1996) Inflammation, free radicals, and antioxidants. Nutrition 12:274-277. [58]Brownlee M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820. [59]Kowluru RA, Kanwar M. (2009) Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Radic Biol Med 46:1677-1685. [60]Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97:12222-12226. [61]Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Srivastava SK. (2003) Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB J 17:417-425. [62]Toth E, Racz A, Toth J, Kaminski PM, Wolin MS, Bagi Z, Koller A.(2007) Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH(2)/TXA(2) mediation. Am J Physiol Heart Circ Physiol 293:H3096-H3104. [63]amagishi S, Nakamura K, Imaizumi T. (2005) Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 1:93-106. [64]Lee AY, Chung SS. (1999) Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13:23-30. [65] Reaven, GM., Role of inssulin resistance in human disease. Diabetes,1988. 37(1):p. 595-607. [66] Howard, B.V., inssulin resistance and lipid metabolism. Am J Cardiol, 1999. 84: p28-23. [67] Mitrakou, A., et al., Contribution of abnormal muscle and Liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes, 1990. 39: p1381-1390. [68] Saltiel, A.R., The molecular and physiological basis of inssulin resistance. J Clin Invest, 2000. 106: p. 165-170. [69]Carrara, M.A., et al., Coexistence of inssulin resistance and increased glucose tolerance in pregnant rats: A physiological mechanism for giucose maintenance.Life Sci, 2012. [70]張建和建,香瓜茄、人參果的營養成分分析研究.廣東微量元素學,2007.14(3):p.48-51. [71]韓青梅,整枝與施肥對澎湖地區香瓜茄產量及品質之影響.高雄區農改場研究會報.2002.14(1):p.22-30. [72]劉蓁蓁,香瓜茄.園藝科學術語,p.267. [73]黃涵,台灣蔬菜彩色圖說.大園藝系編印,1992:p.158. [74]Ren,W.and D.G.Tang,Extract of Solanum muricatum (pepino/CSG)INHIBITS TUMOR GROWTH BY INDUCING APOPTOSIS.Anticancer Res,1999.19(1A):p.403-408.
|